EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation

Kaoru Yoshikawa, Akira Ooki iD, Eiji Shinozaki iD, Eiichiro Toyokawa iD, Keito Suzuki, Manabu Shiozawa iD, Shin Maeda iD, Kensei Yamaguchi iD, Hiroki Osumi iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27167261 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Kaoru Yoshikawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Neoplasm Recurrence, Local, Precision Medicine, Organ Sparing Treatments. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Institute Hospital, Japanese Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Perioperative treatment for colorectal cancer (CRC) is undergoing a paradigm shift from uniform cytotoxic regimens toward strategies guided by tumor location, microsatellite instability (MSI)/mismatch repair (MMR) status, and recurrence risk. Four clinically relevant subgroups now shape decision-making: microsatellite stable (MSS)/proficient MMR (pMMR) colon cancer, microsatellite instability-high (MSI-H)/deficient MMR (dMMR) colon cancer, MSS/pMMR rectal cancer, and MSI-H/dMMR rectal cancer. In MSS/pMMR colon cancer, adjuvant therapy is being refined through risk-adapted treatment duration and selective use of neoadjuvant chemotherapy. In MSS/pMMR rectal cancer, total neoadjuvant therapy, selective omission of pelvic radiotherapy, and watch-and-wait strategies are redefining treatment sequencing and organ preservation. In MSI-H/dMMR colon cancer, immune checkpoint inhibitor (ICI) therapy has shown marked activity in both adjuvant and neoadjuvant settings. In MSI-H/dMMR rectal cancer, neoadjuvant ICI therapy is being explored as a non-operative organ preservation strategy. In parallel, circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assessment is emerging as a tool for postoperative escalation, de-escalation, and surveillance. Across these settings, the maturity of the evidence varies widely, ranging from established phase III standards to guideline-endorsed but still single-arm approaches and investigational strategies that require prospective validation before routine adoption. This review summarizes the current evidence and remaining challenges in biology-, site-, and risk-adapted perioperative management of CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsNeoplasm Recurrence, LocalPrecision MedicineOrgan Sparing TreatmentsPerioperative CareHumansMicrosatellite InstabilityNeoadjuvant TherapyDNA Mismatch Repair

Stichwörter der Autor:innen

circulating tumor DNA (ctDNA)colorectal cancerimmune checkpoint inhibitorminimal residual disease (MRD)mismatch repair deficiencyorgan preservationperioperative therapyrectal cancertotal neoadjuvant therapywatch-and-wait

Autor:innen und Institutionen

  • Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
  • Department of Colorectal Surgery, Kanagawa Cancer Center, Yokohama 241-8515, Japan.
  • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama 241-8515, Japan.

ORCID-Profile: Akira Ooki, Eiji Shinozaki, Eiichiro Toyokawa, Manabu Shiozawa, Shin Maeda, Kensei Yamaguchi, Hiroki Osumi

Förderung

  • Cancer Institute Hospital, Japanese Foundation for Cancer Research

Zitieren

APA

Yoshikawa, K., Ooki, A., Shinozaki, E., Toyokawa, E., Suzuki, K., Shiozawa, M., Maeda, S., Yamaguchi, K., & Osumi, H. (2026). Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27167261

Vancouver

Yoshikawa K, Ooki A, Shinozaki E, Toyokawa E, Suzuki K, Shiozawa M, et al. Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27167261

BibTeX
@article{Yoshikawa2026,
  author = {Yoshikawa, Kaoru and Ooki, Akira and Shinozaki, Eiji and Toyokawa, Eiichiro and Suzuki, Keito and Shiozawa, Manabu and Maeda, Shin and Yamaguchi, Kensei and Osumi, Hiroki},
  title = {Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27167261}
}
Kostenlos starten →